Search

Neuroendocrine prostate cancer is a rapidly progressive and lethal disease characterized by early visceral metastasis, poor prognosis, and limited treatment options. Uncovering the oncogenic mechanisms could lead to the discovery of potential therapeutic avenues. Here, we demonstrate that the RNA-binding protein ELAVL3 is specifically upregulated in neuroendocrine prostate cancer and that overexpression of ELAVL3 alone is sufficient to induce the neuroendocrine phenotype in prostate adenocarcinoma. Mechanistically, ELAVL3 is transcriptionally regulated by MYCN and subsequently binds to and stabilizes MYCN and RICTOR mRNA. Moreover, ELAVL3 is shown to be released in extracellular vesicles and induce neuroendocrine differentiation of adenocarcinoma cells via an intercellular mechanism. Pharmacological inhibition of ELAVL3 with pyrvinium pamoate, an FDA-approved drug, effectively suppresses tumor growth, reduces metastatic risk, and improves survival in neuroendocrine prostate cancer mouse models. Our results identify ELAVL3 as a critical regulator of neuroendocrine differentiation in prostate cancer and propose a drug repurposing strategy for targeted therapies. Neuroendocrine prostate cancer (NEPC) is an aggressive subtype with limited effective therapeutic options. Here, the authors identify the RNA-binding protein ELAVL3 as a driver of differentiation into NEPC via a positive feedback loop with MYCN and demonstrate the use of the repurposed drug pyrvinium pamoate to target this axis using preclinical models of NEPC. [ABSTRACT FROM AUTHOR]

As an important part of the new infrastructure, the cloud data center is developing rapidly, and its energy consumption problem is becoming more and more prominent. Therefore, research on energy-saving technologies for cloud data centers has attracted widespread attention from academia and industry. Some studies have reviewed energy-saving optimization methods and technologies for data centers, but recently, many state-of-the-art optimization methods of energy consumption and energy-saving technologies have sprung out, which are still worth analyzing and discussing. Depending on the in-depth investigation and analysis of related research status, this article firstly focuses on analyzing and discussing the energy-saving technologies of the two components: IT equipment and cooling systems, both of which bring about the largest energy consumption in cloud data centers. As for IT equipment, its energy-saving technologies mainly include the energy saving of servers, storage systems, and network systems. While as for cooling systems, airflow organization in the computer room, thermal-aware scheduling technology, and other new energy-saving technologies are involved. Secondly, on the basis of analyzing the energy-saving technologies of the two major components, a new optimization scheme of energy consumption for the jointing computing system and cooling system is explained. Throughout this work, various energy-saving strategies and technologies have been described and compared. Finally, the future trends and development directions of energy saving for data centers are further promoted, such as integral optimization of energy consumption jointing multiple components, energy saving using artificial intelligence methods, energy saving based on novel hardware equipment, hybrid cooling energy saving, and comprehensive energy conservation with various energy technologies. [ABSTRACT FROM AUTHOR]

Human hexokinase 2 is an essential regulator of glycolysis that couples metabolic and proliferative activities in cancer cells. The binding of hexokinase 2 to the outer membrane of mitochondria is critical for its oncogenic activity. However, the regulation of hexokinase 2 binding to mitochondria remains unclear. Here, we report that SUMOylation regulates the binding of hexokinase 2 to mitochondria. We find that hexokinase 2 can be SUMOylated at K315 and K492. SUMO-specific protease SENP1 mediates the de-SUMOylation of hexokinase 2. SUMO-defective hexokinase 2 preferably binds to mitochondria and enhances both glucose consumption and lactate production and decreases mitochondrial respiration in parallel. This metabolic reprogramming supports prostate cancer cell proliferation and protects cells from chemotherapy-induced cell apoptosis. Moreover, we demonstrate an inverse relationship between SENP1-hexokinase 2 axis and chemotherapy response in prostate cancer samples. Our data provide evidence for a previously uncovered posttranslational modification of hexokinase 2 in cancer cells, suggesting a potentially actionable strategy for preventing chemotherapy resistance in prostate cancer. The oncogenic activity of Hexokinase 2, the first rate-limiting enzyme of glycolysis, requires its mitochondrial localization. Here, the authors show that SUMOylation of hexokinase 2 disrupts its binding to mitochondria and protects cells from tumorigenesis in prostate cancer. [ABSTRACT FROM AUTHOR]